Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Highlights Shortages Risk For Essential Drugs In Canada

A Quarter Of The Top 100 Most Important Medicines Are At High Risk Of Shortage

Executive Summary

With Sandoz Canada having just announced its first list of the top 100 most important medicines for Canadian patients, the company has also highlighted the high risk of shortages for 25 of these drugs. Michel Robidoux, president and general manager at Sandoz Canada, gives Generics Bulletin the details in an exclusive Q&A.

You may also be interested in...



Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval

Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.

GGB Awards Set Stage For Milan In October

The Global Generics & Biosimilars Awards returns to Milan this October, recognizing the top achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

‘Fast Forward Four Or Five Years, We’re Going To Look Very Different’ – Rosemont Chief Eyes ‘Transformative’ International M&A

UK-based liquids specialist Rosemont Pharmaceuticals is on the lookout for M&A opportunities, particularly as it looks to build up its business in the US, chief executive Howard Taylor tells Generics Bulletin in an exclusive interview.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel